This article is more than 5 years old. Information may no longer be current.

RenalytixAI secures funding to complete early detection kidney disease tool

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

RenalytixAI plc has raised $29 million from a network of institutional and industry health care investors. The company, a Mount Sinai licensee and development collaborator, works to develop and commercialize clinical diagnostic solutions for early detection of kidney disease and transplant management, according to a Mount Sinai release.

Part of the proceeds from this public listing will be used to complete a multicenter clinical study with the Icahn School of Medicine at Mount Sinai to validate KidneyIntelX for a 2019 commercial launch. KidneyIntelX will aim for early detection of kidney disease in patients with type 2 diabetes and those of African ancestry.

RenalytixAI will draw from its technology platform to develop the diagnostic tool, using sources which include systems containing extensive electronic health records, predictive blood-based biomarkers and other genomic information for algorithmic analysis.

“RenalytixAI can now bring the clinical and financial resources together to drive advanced diagnostic development to combat the costs and management of kidney disease,” James McCullough, CEO of RenalytixAI, said in the release.

Reference:

www.renalytixai.com